Image pharmaphorum Editor Views & Analysis Transformational therapies demand a new mindset Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges. Views & Analysis Why we need research into the mental health impact of a rare... Rare diseases impact between 3.5%-5.9% of the world’s population. Views & Analysis Expediting innovation in the rare disease domain Rare diseases affect a fraction of the population – 450 million+ peop Views & Analysis Deep Dive: Research and Development Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel. Load more results
Views & Analysis Transformational therapies demand a new mindset Pharma is moving to a new era of radically new therapies, presenting unexpected and difficult challenges.
Views & Analysis Why we need research into the mental health impact of a rare... Rare diseases impact between 3.5%-5.9% of the world’s population.
Views & Analysis Expediting innovation in the rare disease domain Rare diseases affect a fraction of the population – 450 million+ peop
Views & Analysis Deep Dive: Research and Development Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
